secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2026-07-30T11:30:33+00:00
Accession:  0001104659-26-088461
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi selects ulcerative colitis as first indication for STAT3 inhibitor TTI-109 after positive Phase 1 data
--------------------------------------------------------------------------------

- TTI-109 Phase 1 healthy volunteer study showed placebo-adjusted reductions in Th17 (up to 76%), Tfh (up to 43%), and B cells (up to 71%) implicated in UC.
- Company plans to initiate a Phase 2 study in moderate-to-severe UC in 2027, pending IND clearance and funding.
- TTI-109 is an oral small molecule STAT3 inhibitor designed to address immune dysregulation, inflammation, and proliferation.
- KOL webinar with Dr. Randy Longman scheduled for August 19, 2026, to discuss UC treatment landscape and TTI-109 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/0001104659-26-088461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/tm2621651d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer